An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A nasal spray derived from ketamine gets federal clearance to help some people treat depression. The Federal Drug Administration approved "Spravato" from Johnson and Johnson, to be used by people ...

And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to give rapid relief to depression symptoms, was just approved as a stand-alone therapy by the Food and ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

Spravato is a first-of-its-kind medication ... which is the “chemical cousin” of ketamine. Ketamine has been used by clinics across the U.S. to treat depression, anxiety and post-traumatic ...

Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname “Special K”.

Calculate here The approval paves the way for use of Spravato in patients whose disease has stopped responding to at least two oral anti-depressants. "Treatment-resistant depression can be very ...

Spravato, which is derived from ketamine, is not a new drug—it first came on the market in 2019. The spray was previously approved as a companion treatment to an oral antidepressant, as well as ...

However, medication involving the anesthetic, ketamine ... antidepressants, Spravato works as a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor.